Nicla La Verde

Citée par

	Toutes	Depuis 2020
Citations	3041	2175
indice h	28	21
indice i10	49	41

500

250

125

375

20082009201020112012201320142015201620172018201920202021202220232024202524 15 20 26 71 72 77 80 87 107 106 142 326 499 435 418 419 55

Accès public

Tout afficher

15 articles

3 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Marina Chiara GarassinoThe University of ChicagoAdresse e-mail validée de medicine.bsd.uchicago.edu
Anna MorettiASST FATEBENEFRATELLI SACCOAdresse e-mail validée de asst-fbf-sacco.it
daniele santiniprofessor in general pathologyAdresse e-mail validée de unicampus.it
Daniele GeneraliDipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di TriesteAdresse e-mail validée de units.it
Rossana BerardiUniversità Politecnica delle Marche - Ospedali Riuniti di AnconaAdresse e-mail validée de univpm.it
damia giovannaChief, DNA repair unit, Mario negri instituteAdresse e-mail validée de marionegri.it
Diana GiannarelliFondazione Policlinico Universitario A. Gemelli IRCCS RomeAdresse e-mail validée de policlinicogemelli.it
Giuseppe ToniniProfessore ordinario di Oncologia, Università Campus Bio-Medico di RomaAdresse e-mail validée de unicampus.it
Camillo PortaTranslational Oncology, IRCCS Istituti Clinici Scientifici MaugeriAdresse e-mail validée de icsmaugeri.it
bruno vincenziUniversity Campus Bio-MedicoAdresse e-mail validée de unicampus.it
Laura GuarnacciaFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Università degli Studi di MilanoAdresse e-mail validée de policlinico.mi.it
Giuseppe PerroneFull Professor of Pathology, Chief of Pathology Research Unit, Università Campus Bio-Medico di RomaAdresse e-mail validée de unicampus.it
Andrea Onetti Mudaprofessor of pathology, campus biomedico university of romeAdresse e-mail validée de unicampus.it
Luca MoscettiAzienda Ospedaliero Universitaria Policlinico ModenaAdresse e-mail validée de policlinico.mo.it
Marco MerlanoCandiolo cancer institute, FPO - Candiolo (Turin) ItalyAdresse e-mail validée de ircc.it
Francesco CognettiDirettore Oncologia Medica 1 IFO Istituto Nazionale Tumori Regina Elena RomaAdresse e-mail validée de ifo.it
Antonio RussoUniversity of PalermoAdresse e-mail validée de community.unipa.it
Filippo BianchiServizio di Anatomia Patologica, Ospedale Fatebenefratelli-Oftalmico MILANOAdresse e-mail validée de asst-fbf-sacco.it
Grazia Arpinouniversità federico II napoliAdresse e-mail validée de unina.it
Domenico GalettaIRCCS Istituto Tumori "Giovanni Paolo II"-Bari, ItalyAdresse e-mail validée de oncologico.bari.it

Suivre

Nicla La Verde

Luigi Sacco Hospital - ASST Fatebenefratelli Sacco

Adresse e-mail validée de asst-fbf-sacco.it

Oncology


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020	688	2020
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ... PloS one 6 (4), e19234, 2011	216	2011
Natural history of non-small-cell lung cancer with bone metastases D Santini, S Barni, S Intagliata, A Falcone, F Ferraù, D Galetta, L Moscetti, ... Scientific reports 5 (1), 1-9, 2015	130	2015
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018	99	2018
Response of thymoma to cetuximab G Farina, MC Garassino, M Gambacorta, N La Verde, G Gherardi, ... The Lancet Oncology 8 (5), 449-450, 2007	95	2007
The clinical value of nutritional care before and during active cancer treatment G Aprile, D Basile, R Giaretta, G Schiavo, N La Verde, E Corradi, T Monge, ... Nutrients 13 (4), 1196, 2021	91	2021
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives S Gori, M Barberis, MA Bella, F Buttitta, E Capoluongo, P Carrera, ... Critical Reviews in Oncology/Hematology 140, 67-72, 2019	79	2019
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis E Galfrascoli, S Piva, M Cinquini, A Rossi, N La Verde, A Bramati, ... Digestive and Liver Disease 43 (4), 286-294, 2011	75	2011
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis MC Garassino, V Torri, G Michetti, ML Dico, N La Verde, S Aglione, ... Lung Cancer 72 (3), 378-383, 2011	73	2011
T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer A Fabi, D Alesini, E Valle, L Moscetti, R Caputo, M Caruso, L Carbognin, ... The Breast 41, 137-143, 2018	69	2018
Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with … A Bramati, S Girelli, G Farina, MC Dazzani, V Torri, A Moretti, S Piva, ... Journal of bone and mineral metabolism 33, 119-124, 2015	63	2015
Efficacy of biological agents in metastatic triple-negative breast cancer A Bramati, S Girelli, V Torri, G Farina, E Galfrascoli, S Piva, A Moretti, ... Cancer treatment reviews 40 (5), 605-613, 2014	61	2014
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer J van de Haar, X Ma, SN Ooft, PW van der Helm, LR Hoes, S Mainardi, ... Nature Medicine 29 (3), 605-614, 2023	56	2023
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world … L Cantini, G Mentrasti, GL Russo, D Signorelli, G Pasello, E Rijavec, ... ESMO open 7 (2), 100406, 2022	55	2022
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study G Bon, L Pizzuti, V Laquintana, R Loria, M Porru, C Marchiò, E Krasniqi, ... Journal of Experimental & Clinical Cancer Research 39, 1-14, 2020	53	2020
The prognostic role of tumor size in early breast cancer in the era of molecular biology AA Kasangian, G Gherardi, E Biagioli, V Torri, A Moretti, E Bernardin, ... PloS one 12 (12), e0189127, 2017	52	2017
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies A Russo, L Incorvaia, E Capoluongo, P Tagliaferri, S Gori, L Cortesi, ... ESMO open 7 (3), 100459, 2022	49	2022
Tumor-educated platelets and angiogenesis in glioblastoma: another brick in the wall for novel prognostic and targetable biomarkers, changing the vision from a localized tumor … R Campanella, L Guarnaccia, C Cordiglieri, E Trombetta, M Caroli, ... Cells 9 (2), 294, 2020	47	2020
Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution N La Verde, C Bareggi, M Garassino, K Borgonovo, P Sburlati, D Pedretti, ... Supportive care in cancer 16, 1311-1315, 2008	46	2008
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel+ trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer SA Jacobs, A Robidoux, J Abraham, JM Pérez-Garcia, N La Verde, ... Breast Cancer Research 21, 1-11, 2019	43	2019

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs